Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
Headlines
Pujiang Prostate Cancer Academic Conference | Prof. Fangning Wan: Innovations in Local Therapy, Advances in Systemic Treatment, and Clinical Applications of Cryotherapy for Prostate Cancer
2026.08.06
Advances in ADC Therapy for Advanced Urothelial Carcinoma | Prof. Kaiwei Yang Reviews the Evolving First- and Later-Line Treatment Landscape
2026.08.06
Prof. Benkang Shi: Building Academic Synergy Across the Yellow River Region to Advance High-Quality Development of Urology in Shandong
2026.08.06
CUDA 2026 | Prof. Xiaoying Li: From Technological Innovation to MDT Collaboration—Redefining the Landscape of Urologic Oncology
2026.08.06
BOC 2026 | Prof. Pei Dong: Kidney Cancer Enters the Era of Long-Term Survival, with New Advances in Adjuvant Therapy and Comprehensive Disease Management
2026.08.05
BOC 2026 | Prof. Wasilijiang-Wahafu: Neoadjuvant Therapy for MIBC Enters a New Era with Precision Stratification and Comprehensive Perioperative Management
2026.08.05
CUDA 2026 | Prof. Nianzeng Xing: Advancing Urology Through Collaboration and Innovation
2026.08.05
CUDA 2026 | Rethinking Tiered Healthcare and Multidisciplinary Care in Urology—An Interview with Prof. Zhisong He
2026.08.05
CUDA 2026 | Prof. Xingyuan Xiao: Rethinking Comprehensive Urologic Cancer Management Through the Integration of Traditional Chinese and Western Medicine and MDT
2026.08.04
CUDA 2026 | Prof. Zhaohui Gu: Advancing Intelligent Surgery and Precision Treatment to Shape the Future of Urology
2026.08.04
Posted inIOncology UroStream

Pujiang Prostate Cancer Academic Conference | Prof. Fangning Wan: Innovations in Local Therapy, Advances in Systemic Treatment, and Clinical Applications of Cryotherapy for Prostate Cancer

Posted by By Peter W. PENG 2026.08.06
Continue Reading
Posted inIOncology UroStream

Advances in ADC Therapy for Advanced Urothelial Carcinoma | Prof. Kaiwei Yang Reviews the Evolving First- and Later-Line Treatment Landscape

Posted by By Peter W. PENG 2026.08.06
Continue Reading
Anlotinib: A Promising Therapeutic Approach for Transformed Follicular Lymphoma

Anlotinib: A Promising Therapeutic Approach for Transformed Follicular Lymphoma

Posted by By Mourabit Halima 2024.03.18
Introduction: Transformed follicular lymphoma (tFL) presents a formidable challenge in clinical oncology due to its high tumor mutational burden and therapeutic resistance. While anlotinib has demonstrated efficacy in solid tumors,…
Read More
The Role of SHP-1 and SHP-2 in CD8+ T Cell Regulation during Lymphocytic Choriomeningitis Virus Infection: Insights into Stage-Specific Functional Interplay

The Role of SHP-1 and SHP-2 in CD8+ T Cell Regulation during Lymphocytic Choriomeningitis Virus Infection: Insights into Stage-Specific Functional Interplay

Posted by By Mourabit Halima 2024.03.18
Abstract: Our study delves into the intricate interplay between Src homology region 2 domain-containing phosphatases 1 and 2 (SHP-1 and SHP-2) in orchestrating the functionality of CD8+ T cells during…
Read More
Assessing the Impact of Omicron Variant on Allo-HSCT Recipients in China: Insights from a Single-Center Observational Study

Assessing the Impact of Omicron Variant on Allo-HSCT Recipients in China: Insights from a Single-Center Observational Study

Posted by By Mourabit Halima 2024.03.17
Introduction: The emergence of the Omicron variant of SARS-CoV-2 has posed significant challenges to global public health systems. Among vulnerable populations, allo-hematopoietic stem cell transplantation (allo-HSCT) recipients represent a particularly…
Read More

The Complex Impact of CMV Reactivation Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Comprehensive Review

Posted by By Qingyuan Liu 2024.03.17
Abstract: Cytomegalovirus (CMV) reactivation presents a formidable challenge for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), with implications for overall mortality (OM) and non-relapse mortality (NRM) that are subject…
Read More
Allogeneic Hematopoietic Stem Cell Transplantation: A Salvage Option for Diffuse Large B-Cell Lymphoma Patients After CAR-T Therapy Failure

Allogeneic Hematopoietic Stem Cell Transplantation: A Salvage Option for Diffuse Large B-Cell Lymphoma Patients After CAR-T Therapy Failure

Posted by By Yang Xiaoshan 2024.03.17
Abstract: Refractory/relapsed diffuse large B-cell lymphoma (R/R DLBCL) poses significant therapeutic challenges, particularly in cases where chimeric antigen receptor T-cell (CAR-T) therapy fails. This retrospective study aimed to evaluate the…
Read More
Exploring CD22 as an Alternative Target in B-cell Hematologic Malignancies: A Comprehensive Review of Study Design, Clinical Implications, and Future Perspectives

Exploring CD22 as an Alternative Target in B-cell Hematologic Malignancies: A Comprehensive Review of Study Design, Clinical Implications, and Future Perspectives

Posted by By Mourabit Halima 2024.03.17
Abstract: Chimeric antigen receptor (CAR)-T cell therapy targeting CD19 has revolutionized the treatment landscape for patients with relapsed or refractory (R/R) B-cell malignancies. However, the emergence of relapse with CD19-negative…
Read More
Bispecific CS1-BCMA CAR-T Cells Show Promise in Treating Relapsed or Refractory Multiple Myeloma: Phase I Clinical Trial Results

Bispecific CS1-BCMA CAR-T Cells Show Promise in Treating Relapsed or Refractory Multiple Myeloma: Phase I Clinical Trial Results

Posted by By Mourabit Halima 2024.03.17
Abstract: Multiple myeloma (MM) poses significant therapeutic challenges due to its heterogeneous nature. Bispecific chimeric antigen receptor T (CAR-T) cell therapy targeting CS1 and BCMA antigens offers a novel approach.…
Read More
Evaluating the Efficacy and Safety of Orelabrutinib-Based Regimens in Diffuse Large B-Cell Lymphoma: A Retrospective Analysis

Evaluating the Efficacy and Safety of Orelabrutinib-Based Regimens in Diffuse Large B-Cell Lymphoma: A Retrospective Analysis

Posted by By Mourabit Halima 2024.03.17
Abstract: Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous malignancy associated with significant morbidity and mortality. Orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown promise as a therapeutic agent…
Read More
Retrospective Analysis of bZIP Region Mutations in CEBPA Double-Mutated Acute Myeloid Leukemia: Implications for Prognosis and Treatment

Retrospective Analysis of bZIP Region Mutations in CEBPA Double-Mutated Acute Myeloid Leukemia: Implications for Prognosis and Treatment

Posted by By Mourabit Halima 2024.03.17
Editor's note: Acute Myeloid Leukemia (AML) characterized by CCAAT-enhancer binding protein alpha (CEBPA) double mutations (CEBPAdm) represents a distinct subtype with varying clinical outcomes. Recent attention has focused on the…
Read More
The Impact of CEBPA Mutations in Hematological Disorders: A Comprehensive Study

The Impact of CEBPA Mutations in Hematological Disorders: A Comprehensive Study

Posted by By Mourabit Halima 2024.03.17
Editor's note: Genetic mutations play a pivotal role in shaping the clinical presentation and prognosis of hematological disorders, with CEBPA mutations emerging as significant contributors to disease pathogenesis. This comprehensive…
Read More

Posts pagination

Previous page 1 … 20
Recent Posts
  • Pujiang Prostate Cancer Academic Conference | Prof. Fangning Wan: Innovations in Local Therapy, Advances in Systemic Treatment, and Clinical Applications of Cryotherapy for Prostate Cancer
  • Advances in ADC Therapy for Advanced Urothelial Carcinoma | Prof. Kaiwei Yang Reviews the Evolving First- and Later-Line Treatment Landscape
  • Prof. Benkang Shi: Building Academic Synergy Across the Yellow River Region to Advance High-Quality Development of Urology in Shandong
  • CUDA 2026 | Prof. Xiaoying Li: From Technological Innovation to MDT Collaboration—Redefining the Landscape of Urologic Oncology
  • BOC 2026 | Prof. Pei Dong: Kidney Cancer Enters the Era of Long-Term Survival, with New Advances in Adjuvant Therapy and Comprehensive Disease Management
Recent Comments
    Archives
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    Post You Might Like
    Posted inIOncology UroStream
    Pujiang Prostate Cancer Academic Conference | Prof. Fangning Wan: Innovations in Local Therapy, Advances in Systemic Treatment, and Clinical Applications of Cryotherapy for Prostate Cancer
    Posted by By Peter W. PENG 2026.08.06
    Posted inIOncology UroStream
    Advances in ADC Therapy for Advanced Urothelial Carcinoma | Prof. Kaiwei Yang Reviews the Evolving First- and Later-Line Treatment Landscape
    Posted by By Peter W. PENG 2026.08.06
    Posted inIOncology
    Prof. Benkang Shi: Building Academic Synergy Across the Yellow River Region to Advance High-Quality Development of Urology in Shandong
    Posted by By Mourabit Halima 2026.08.06
    Posted inIOncology
    CUDA 2026 | Prof. Xiaoying Li: From Technological Innovation to MDT Collaboration—Redefining the Landscape of Urologic Oncology
    Posted by By Mourabit Halima 2026.08.06
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top

    Welcome to Mediamedic 👋
    It’s nice to meet you.

    Dive into a world of trusted health insights. Subscribe for monthly updates straight to your inbox

    Privacy is part of our care. No spam, just wellness.

    🔒 Privacy policy

    Check your inbox or spam folder to confirm your subscription.

    • Facebook
    • X (Twitter)
    • LinkedIn
    • More Networks
    Share via
    Facebook
    X (Twitter)
    LinkedIn
    Mix
    Email
    Print
    Copy Link
    Copy link
    CopyCopied